|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
CA3112043A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
US12208099B2
(en)
|
2018-09-10 |
2025-01-28 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
SMT202500028T1
(it)
|
2018-09-10 |
2025-03-12 |
Mirati Therapeutics Inc |
Terapie combinate
|
|
AU2019338207B2
(en)
|
2018-09-10 |
2025-01-02 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020085504A1
(ja)
|
2018-10-26 |
2020-04-30 |
大鵬薬品工業株式会社 |
光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
|
|
US12377101B2
(en)
|
2018-12-05 |
2025-08-05 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020146613A1
(en)
|
2019-01-10 |
2020-07-16 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
CN114615981B
(zh)
|
2019-08-29 |
2024-04-12 |
米拉蒂治疗股份有限公司 |
Kras g12d抑制剂
|
|
CN114761012B
(zh)
|
2019-09-24 |
2025-03-21 |
米拉蒂治疗股份有限公司 |
组合疗法
|
|
MD4051678T2
(en)
|
2019-10-28 |
2026-07-31 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of the KRAS G12C mutant
|
|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
EP4015520B1
(en)
*
|
2019-12-02 |
2025-02-19 |
280 Bio, Inc. |
Oxygen-containing heterocyclic compound, preparation method and application thereof
|
|
PH12022551513A1
(en)
|
2019-12-20 |
2023-04-24 |
Mirati Therapeutics Inc |
Sos1 inhibitors
|
|
US12702658B2
(en)
|
2020-04-24 |
2026-08-11 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
|
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
CN115916194A
(zh)
|
2020-06-18 |
2023-04-04 |
锐新医药公司 |
用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
|
|
WO2022002102A1
(en)
*
|
2020-06-30 |
2022-01-06 |
InventisBio Co., Ltd. |
Quinazoline compounds, preparation methods and uses thereof
|
|
US12655160B2
(en)
|
2020-08-04 |
2026-06-16 |
Mirati Therapeutics, Inc. |
KRAS G12D inhibitors
|
|
EP4208261A1
(en)
|
2020-09-03 |
2023-07-12 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
EP4210833A4
(en)
|
2020-09-11 |
2024-09-11 |
Mirati Therapeutics, Inc. |
CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
|
|
EP4216951B1
(en)
|
2020-09-22 |
2026-04-01 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
CN116323624B
(zh)
*
|
2020-09-30 |
2026-07-10 |
上海医药集团股份有限公司 |
一种喹唑啉类化合物及其应用
|
|
US20240034733A1
(en)
|
2020-11-03 |
2024-02-01 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
WO2022105855A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras g12d inhibitors
|
|
CN116490508A
(zh)
*
|
2020-11-20 |
2023-07-25 |
北京加科思新药研发有限公司 |
Kras g12d抑制剂
|
|
WO2022105859A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras g12d inhibitors
|
|
WO2022109487A1
(en)
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
EP4262807A4
(en)
|
2020-12-15 |
2025-04-23 |
Mirati Therapeutics, Inc. |
Azachinazoline pan-KRAS inhibitors
|
|
WO2022133038A1
(en)
|
2020-12-16 |
2022-06-23 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
US20240092803A1
(en)
*
|
2021-01-08 |
2024-03-21 |
Beigene Switzerland Gmbh |
Bridged compounds as kras g12d inhibitor and degrader and the use thereof
|
|
WO2022148422A1
(en)
*
|
2021-01-08 |
2022-07-14 |
Beigene, Ltd. |
Bridged compounds as kras g12d inhibitor and degrader and the use thereof
|
|
TWI793999B
(zh)
*
|
2021-02-01 |
2023-02-21 |
大陸商南京明德新藥研發有限公司 |
嘧啶並吡喃化合物
|
|
WO2022171143A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南京明德新药研发有限公司 |
5,6,7,8-四氢吡啶[3,4-d]嘧啶化合物
|
|
JP2024505594A
(ja)
*
|
2021-02-09 |
2024-02-06 |
メッドシャイン ディスカバリー インコーポレイテッド |
ピリミジン芳香環化合物
|
|
WO2022170999A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南京明德新药研发有限公司 |
吡啶[4,3-d]嘧啶类化合物
|
|
LT4293024T
(lt)
|
2021-02-15 |
2026-05-25 |
Astellas Pharma Inc. |
Chinazolino junginys, skirtas g12d mutantinio kras baltymo degradacijai sukelti
|
|
CA3211110A1
(en)
*
|
2021-02-15 |
2022-08-18 |
Astellas Pharma Inc. |
4-aminoquinazoline compound
|
|
KR20230169967A
(ko)
*
|
2021-03-12 |
2023-12-18 |
브리스톨-마이어스 스큅 컴퍼니 |
Kras g12d 억제제
|
|
WO2022194066A1
(zh)
*
|
2021-03-15 |
2022-09-22 |
贝达药业股份有限公司 |
Kras g12d抑制剂及其在医药上的应用
|
|
TWI810803B
(zh)
*
|
2021-03-15 |
2023-08-01 |
大陸商藥雅科技(上海)有限公司 |
突變蛋白抑制劑的製備及其應用
|
|
WO2022194192A1
(zh)
*
|
2021-03-18 |
2022-09-22 |
四川科伦博泰生物医药股份有限公司 |
一类杂芳环化合物、其制备方法及用途
|
|
CN116157400B
(zh)
*
|
2021-03-30 |
2024-10-22 |
浙江海正药业股份有限公司 |
杂环类衍生物及其制备方法和用途
|
|
WO2022217042A1
(en)
*
|
2021-04-09 |
2022-10-13 |
Ikena Oncology, Inc. |
Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
|
|
WO2022223020A1
(zh)
*
|
2021-04-23 |
2022-10-27 |
清华大学 |
靶向活化与失活态kras g12d的抑制剂
|
|
WO2022232331A1
(en)
*
|
2021-04-29 |
2022-11-03 |
Amgen Inc. |
Heterocyclic compounds and methods of use
|
|
CN117561063A
(zh)
*
|
2021-04-29 |
2024-02-13 |
安进公司 |
杂环化合物及使用方法
|
|
EP4332105A4
(en)
*
|
2021-04-30 |
2025-05-28 |
Genfleet Therapeutics (Shanghai) Inc. |
PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE
|
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
CN115385937A
(zh)
*
|
2021-05-25 |
2022-11-25 |
江苏恒瑞医药股份有限公司 |
嘧啶并环烷基类化合物、其制备方法及其在医药上的应用
|
|
CN117769554A
(zh)
*
|
2021-05-28 |
2024-03-26 |
大鹏药品工业株式会社 |
Kras突变蛋白的小分子抑制剂
|
|
CN117500799A
(zh)
*
|
2021-06-09 |
2024-02-02 |
伊莱利利公司 |
作为kras g12d抑制剂的取代的稠合吖嗪
|
|
WO2022258974A1
(en)
*
|
2021-06-10 |
2022-12-15 |
Redx Pharma Plc |
Quinazoline derivatives useful as ras inhibitiors
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
WO2022262838A1
(en)
*
|
2021-06-18 |
2022-12-22 |
Silexon Ai Technology Co., Ltd. |
Deuterated compounds useful as kras g12d inhibitors
|
|
MX2023015533A
(es)
*
|
2021-06-21 |
2024-01-23 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
|
|
CA3221811A1
(en)
*
|
2021-06-30 |
2023-01-05 |
Dana-Farber Cancer Institute, Inc. |
Small molecule inhibitors of kras g12d mutant
|
|
WO2023280026A1
(zh)
*
|
2021-07-05 |
2023-01-12 |
四川科伦博泰生物医药股份有限公司 |
杂芳环化合物、其制备方法及用途
|
|
WO2023280280A1
(zh)
*
|
2021-07-07 |
2023-01-12 |
微境生物医药科技(上海)有限公司 |
作为KRas G12D抑制剂的稠环化合物
|
|
WO2023284730A1
(en)
*
|
2021-07-14 |
2023-01-19 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
|
WO2023283933A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Silexon Biotech Co., Ltd. |
Compounds useful as kras g12d inhibitors
|
|
CN117157292A
(zh)
*
|
2021-07-16 |
2023-12-01 |
苏州赞荣医药科技有限公司 |
Kras g12d抑制剂和其用途
|
|
WO2023284881A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Silexon Ai Technology Co., Ltd. |
Heterocyclic compounds useful as kras g12d inhibitors
|
|
EP4378478A4
(en)
|
2021-07-27 |
2025-11-12 |
Toray Industries |
MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
|
|
EP4382133A4
(en)
*
|
2021-08-06 |
2025-06-18 |
Interoligo Corporation |
Pharmaceutical composition for the treatment of triple-negative breast cancer with non-natural nucleic acid ligand as active ingredient
|
|
CN116143806A
(zh)
*
|
2021-08-08 |
2023-05-23 |
上海凌达生物医药有限公司 |
一类含氮杂环类化合物、制备方法和用途
|
|
EP4384522A1
(en)
*
|
2021-08-10 |
2024-06-19 |
Erasca, Inc. |
Selective kras inhibitors
|
|
US20240327929A1
(en)
*
|
2021-08-12 |
2024-10-03 |
Merck Sharp & Dohme Llc |
Dosage regimen for administration of belzutifan
|
|
WO2023020347A1
(zh)
*
|
2021-08-16 |
2023-02-23 |
华润医药研究院(深圳)有限公司 |
嘧啶并吡啶类化合物及其制备方法和医药用途
|
|
WO2023020518A1
(en)
*
|
2021-08-18 |
2023-02-23 |
Jacobio Pharmaceuticals Co., Ltd. |
N-cyclopropylpyrido [4, 3-d] pyrimidin-4-amine derivatives and uses thereof
|
|
WO2023020519A1
(en)
*
|
2021-08-18 |
2023-02-23 |
Jacobio Pharmaceuticals Co., Ltd. |
1, 4-oxazepane derivatives and uses thereof
|
|
CN117222646A
(zh)
*
|
2021-09-16 |
2023-12-12 |
苏州赞荣医药科技有限公司 |
Kras g12c抑制剂和其用途
|
|
WO2023051586A1
(zh)
*
|
2021-09-29 |
2023-04-06 |
先声再明医药有限公司 |
Kras g12d抑制剂化合物及其制备方法和应用
|
|
KR20240073115A
(ko)
|
2021-10-05 |
2024-05-24 |
미라티 테라퓨틱스, 인크. |
이리노테칸과 kras g12d 억제제의 조합 및 관련된 치료 방법
|
|
KR20240089340A
(ko)
|
2021-10-05 |
2024-06-20 |
미라티 테라퓨틱스, 인크. |
범 ErbB 계열 억제제와 KRAS G12D 억제제의 병용 요법
|
|
EP4412719A4
(en)
*
|
2021-10-05 |
2025-08-13 |
Mirati Therapeutics Inc |
COMBINATION THERAPIES BASED ON KRAS G12D INHIBITORS AND SHP-2 INHIBITORS
|
|
AU2022359282A1
(en)
*
|
2021-10-05 |
2024-04-11 |
Mirati Therapeutics, Inc. |
Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment
|
|
EP4419686A4
(en)
*
|
2021-10-21 |
2025-10-15 |
Nanothera Biosciences Inc |
COMPOSITIONS AND METHODS OF EXTINGUISHING KRAS
|
|
CN114057776A
(zh)
*
|
2021-10-31 |
2022-02-18 |
南京碳硅人工智能生物医药技术研究院有限公司 |
一种具有抗癌活性的嘧啶并哌啶衍生物的新合成方法
|
|
WO2023103523A1
(zh)
*
|
2021-12-09 |
2023-06-15 |
苏州浦合医药科技有限公司 |
取代的双环杂芳基化合物作为kras g12d抑制剂
|
|
WO2023119677A1
(en)
*
|
2021-12-24 |
2023-06-29 |
Astellas Pharma Inc. |
Pharmaceutical composition comprising a quinazoline compound
|
|
CN118434740A
(zh)
*
|
2021-12-31 |
2024-08-02 |
上海医药集团股份有限公司 |
一种喹唑啉类化合物及其应用
|
|
JP7629580B1
(ja)
*
|
2022-01-21 |
2025-02-13 |
ユーシノヴァ・ファーマシューティカルズ・リミテッド |
ベンゾピリミジン化合物及びその使用
|
|
IL314400A
(en)
*
|
2022-01-21 |
2024-09-01 |
D3 Bio Wuxi Co Ltd |
Bridged ring-substituted heteroaryl pyran derivatives and their uses
|
|
WO2023138524A1
(zh)
*
|
2022-01-24 |
2023-07-27 |
贝达药业股份有限公司 |
Kras g12d降解剂及其在医药上的应用
|
|
CA3243798A1
(en)
|
2022-02-09 |
2023-08-17 |
Quanta Therapeutics, Inc. |
Kras Modulators and Their Uses
|
|
US20250154170A1
(en)
*
|
2022-02-10 |
2025-05-15 |
Bayer Aktiengesellschaft |
Fused pyrimidines as kras inhibitors
|
|
CA3255513A1
(en)
|
2022-03-11 |
2025-03-04 |
Astellas Pharma Inc. |
HETEROCYCLIC COMPOUND TO INDUCE DETERIORATION OF G12D MUTATION KRAS PROTEIN
|
|
WO2023179629A1
(zh)
*
|
2022-03-22 |
2023-09-28 |
苏州泽璟生物制药股份有限公司 |
取代桥环类抑制剂及其制备方法和应用
|
|
CN116891488B
(zh)
|
2022-04-11 |
2025-12-12 |
成都海博为药业有限公司 |
稠环化合物、包含其的药物组合物及应用
|
|
US20230365595A1
(en)
*
|
2022-05-13 |
2023-11-16 |
Ranok Therapeutics (Hangzhou) Co. Ltd. |
Inhibitors of kras(g12d)
|
|
WO2023230190A1
(en)
|
2022-05-25 |
2023-11-30 |
Quanta Therapeutics, Inc. |
Pyrimidine based modulators and uses thereof
|
|
CN114989195B
(zh)
*
|
2022-05-25 |
2024-10-29 |
广东晨康生物科技有限公司 |
一种噻吩并嘧啶类化合物或其药学上可接受的盐及其制备方法和应用
|
|
CN117164580A
(zh)
*
|
2022-05-27 |
2023-12-05 |
苏州泽璟生物制药股份有限公司 |
一种kras g12c抑制剂的制备方法及其中间体
|
|
KR20250034963A
(ko)
*
|
2022-06-24 |
2025-03-11 |
메드샤인 디스커버리 아이엔씨. |
헤테로사이클릭 치환 피리미도피란 화합물 및 이의 용도
|
|
WO2024019103A1
(ja)
|
2022-07-21 |
2024-01-25 |
アステラス製薬株式会社 |
G12d変異krasタンパクに作用する複素環化合物
|
|
KR20250037564A
(ko)
*
|
2022-07-29 |
2025-03-17 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
Kras g12d 억제제를 포함하는 약학적 조성물
|
|
TW202412789A
(zh)
|
2022-08-05 |
2024-04-01 |
日商安斯泰來製藥股份有限公司 |
用於誘導突變kras蛋白分解之雜環化合物
|
|
AU2023322690A1
(en)
*
|
2022-08-12 |
2025-03-20 |
Astellas Pharma Inc. |
Anti cancer combinations comprising chemotherapy
|
|
EP4568674A1
(en)
|
2022-08-12 |
2025-06-18 |
Astellas Pharma Inc. |
Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
|
|
JP2025528836A
(ja)
|
2022-08-17 |
2025-09-02 |
ツリーライン バイオサイエンシズ インコーポレイテッド |
ピリドピリミジンKRas阻害剤
|
|
EP4577214A2
(en)
*
|
2022-08-26 |
2025-07-02 |
Merck Sharp & Dohme LLC |
Small molecule inhibitors of kras proteins
|
|
WO2024064335A1
(en)
*
|
2022-09-23 |
2024-03-28 |
Ikena Oncology, Inc. |
Naphthyl-substituted pyranopyrimidinones and related compounds and their use in treating medical conditions
|
|
CN117800976A
(zh)
*
|
2022-09-30 |
2024-04-02 |
上海凌达生物医药有限公司 |
一类含氮杂环类化合物、制备方法和用途
|
|
EP4631942A1
(en)
|
2022-10-21 |
2025-10-15 |
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. |
Pan-kras degrading agent, and preparation method therefor and use thereof
|
|
CN117917416A
(zh)
|
2022-10-21 |
2024-04-23 |
上海领泰生物医药科技有限公司 |
Kras g12d降解剂及其制备方法和应用
|
|
CN116554208A
(zh)
*
|
2022-12-02 |
2023-08-08 |
苏州浦合医药科技有限公司 |
取代的双环杂芳基化合物作为kras g12d抑制剂
|
|
PE20260006A1
(es)
|
2023-01-26 |
2026-01-06 |
Arvinas Operations Inc |
Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
|
|
EP4680609A1
(en)
|
2023-03-15 |
2026-01-21 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
TW202438503A
(zh)
*
|
2023-03-23 |
2024-10-01 |
大陸商南京明德新藥研發有限公司 |
雜環取代的嘧啶並吡喃類化合物及其應用
|
|
CN122180685A
(zh)
*
|
2023-03-27 |
2026-06-09 |
深圳市原力生命科学有限公司 |
用于降解和抑制kras(g12d)蛋白的化合物
|
|
CN121487738A
(zh)
|
2023-03-30 |
2026-02-06 |
锐新医药公司 |
诱导ras gtp水解的组合物和其用途
|
|
KR20260019479A
(ko)
|
2023-05-04 |
2026-02-10 |
레볼루션 메디슨즈, 인크. |
Ras 관련 질환 또는 장애를 위한 병용 요법
|
|
WO2024243441A1
(en)
|
2023-05-24 |
2024-11-28 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
AR133028A1
(es)
|
2023-06-22 |
2025-08-20 |
Astellas Pharma Inc |
Composición farmacéutica que comprende un degradador de todas las kras
|
|
AR133027A1
(es)
|
2023-06-22 |
2025-08-20 |
Astellas Pharma Inc |
Composición farmacéutica que comprende un compuesto de quinazolina
|
|
WO2025019823A1
(en)
*
|
2023-07-20 |
2025-01-23 |
Merck Sharp & Dohme Llc |
Small molecule protein degraders of kras g12d mutant
|
|
WO2025026903A1
(en)
*
|
2023-07-31 |
2025-02-06 |
Bayer Aktiengesellschaft |
Imidazo pyrimidine compounds for the treatment of cancer
|
|
CN121889155A
(zh)
|
2023-08-07 |
2026-04-17 |
锐新医药公司 |
用于治疗ras蛋白相关疾病或病症的rmc-6291
|
|
WO2025064848A1
(en)
|
2023-09-21 |
2025-03-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyridine kras inhibitors
|
|
KR20260110993A
(ko)
|
2023-10-09 |
2026-07-14 |
인사이트 코포레이션 |
Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
|
|
US20250114346A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
KR20260096846A
(ko)
|
2023-10-20 |
2026-06-24 |
머크 샤프 앤드 돔 엘엘씨 |
Kras 단백질의 소분자 억제제
|
|
WO2025108479A1
(en)
*
|
2023-11-24 |
2025-05-30 |
Shenzhen Ionova Life Science Co., Ltd. |
Compounds for degradation or inhibition of kras mutant proteins and uses thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025218811A1
(zh)
*
|
2024-04-19 |
2025-10-23 |
领泰生物医药(绍兴)有限公司 |
pan-KRAS靶向蛋白降解剂及其制备方法和应用
|
|
WO2025230961A1
(en)
*
|
2024-04-29 |
2025-11-06 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2025240740A1
(en)
*
|
2024-05-15 |
2025-11-20 |
Merck Sharp & Dohme Llc |
Small molecule protein degraders of kras g12d mutant
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
US20260137674A1
(en)
|
2024-10-23 |
2026-05-21 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
|
|
WO2026090333A1
(en)
|
2024-10-23 |
2026-04-30 |
Incyte Corporation |
Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer
|
|
WO2026106912A1
(en)
|
2024-11-12 |
2026-05-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026112260A1
(en)
|
2024-11-21 |
2026-05-28 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026122764A2
(en)
|
2024-12-06 |
2026-06-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026128688A2
(en)
|
2024-12-13 |
2026-06-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026161839A1
(en)
|
2025-01-27 |
2026-07-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|